Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 240

1.

Predictive value of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio for the prevention of stroke recurrence in Japanese patients treated with rosuvastatin.

Igase M, Kohara K, Katagi R, Yamashita S, Fujisawa M, Miki T.

Clin Drug Investig. 2012 Aug 1;32(8):513-21. doi: 10.2165/11633950-000000000-00000.

PMID:
22741749
[PubMed - indexed for MEDLINE]
2.

Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.

Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.

Am J Geriatr Pharmacother. 2007 Sep;5(3):185-94.

PMID:
17996658
[PubMed - indexed for MEDLINE]
3.

LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.

Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH.

Curr Med Res Opin. 2005 Nov;21(11):1865-74.

PMID:
16307708
[PubMed - indexed for MEDLINE]
4.

One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.

Ferdinand KC, Davidson MH, Kelly MT, Setze CM.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):117-25. doi: 10.2165/11597940-000000000-00000.

PMID:
22263674
[PubMed - indexed for MEDLINE]
5.

Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.

Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP.

Expert Opin Pharmacother. 2008 Apr;9(5):669-76. doi: 10.1517/14656566.9.5.669.

PMID:
18345946
[PubMed - indexed for MEDLINE]
6.

Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.

Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.

J Atheroscler Thromb. 2011;18(11):1018-28. Epub 2011 Sep 15.

PMID:
21921413
[PubMed - indexed for MEDLINE]
Free Article
7.

Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.

McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; CORONA Study Group.

Circulation. 2009 Dec 1;120(22):2188-96. doi: 10.1161/CIRCULATIONAHA.109.849117. Epub 2009 Nov 16. Erratum in: Circulation. 2010 Jun 29;121(25):e461.

PMID:
19917888
[PubMed - indexed for MEDLINE]
Free Article
8.

The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.

Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M; DISCOVERY PENTA investigators.

Curr Med Res Opin. 2005 Aug;21(8):1307-15.

PMID:
16083541
[PubMed - indexed for MEDLINE]
9.

Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).

Ballantyne CM, Pitt B, Loscalzo J, Cain VA, Raichlen JS.

Am J Cardiol. 2013 Feb 15;111(4):506-9. doi: 10.1016/j.amjcard.2012.10.037. Epub 2012 Dec 10.

PMID:
23237107
[PubMed - indexed for MEDLINE]
10.
11.

Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.

Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Davidson MH.

Clin Ther. 2007 Nov;29(11):2385-94.

PMID:
18158079
[PubMed - indexed for MEDLINE]
12.

Effect of two intensive statin regimens on progression of coronary disease.

Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE.

N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15.

PMID:
22085316
[PubMed - indexed for MEDLINE]
Free Article
13.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

PMID:
20031900
[PubMed - indexed for MEDLINE]
Free Article
14.

Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Kones R.

Drug Des Devel Ther. 2011;5:325-80. doi: 10.2147/DDDT.S14934. Epub 2011 Jun 13. Review.

PMID:
21792295
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.

Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS.

Clin Ther. 2007 Jul;29(7):1403-14.

PMID:
17825691
[PubMed - indexed for MEDLINE]
17.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
[PubMed - indexed for MEDLINE]
18.

Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.

Yun KH, Shin SN, Ko JS, Rhee SJ, Kim NH, Oh SK, Jeong JW.

J Cardiol. 2012 Nov;60(5):383-8. doi: 10.1016/j.jjcc.2012.07.008. Epub 2012 Aug 11.

PMID:
22884684
[PubMed - indexed for MEDLINE]
Free Article
19.

Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.

Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K.

J Clin Lipidol. 2012 Nov-Dec;6(6):534-44. doi: 10.1016/j.jacl.2012.02.002. Epub 2012 Feb 8.

PMID:
23312049
[PubMed - indexed for MEDLINE]
20.

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.

Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.

Am Heart J. 2006 May;151(5):975.e1-9.

PMID:
16644314
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk